I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Phase I study of the combination of crizotinib (as a MET in..:
Kato, Shumei
;
Jardim, Denis L.
;
Johnson, Faye M.
...
Investigational New Drugs. 36 (2017) 3 - p. 416-423 , 2017
Link:
https://doi.org/10.1007/s10637-017-0513-5
RT Journal T1
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer
UL https://suche.suub.uni-bremen.de/peid=cr-10.1007_s10637-017-0513-5&Exemplar=1&LAN=DE A1 Kato, Shumei A1 Jardim, Denis L. A1 Johnson, Faye M. A1 Subbiah, Vivek A1 Piha-Paul, Sarina A1 Tsimberidou, Apostolia M. A1 Falchook, Gerald S. A1 Karp, Daniel A1 Zinner, Ralph A1 Wheler, Jennifer A1 Janku, Filip A1 Fu, Siqing A1 Lim, JoAnn A1 Bean, Stacie A1 Nguyen, Ly A1 Urban, Susan A1 Browne, Elsa A1 Meric-Bernstam, Funda A1 Hong, David S. PB Springer Science and Business Media LLC YR 2017 SN 0167-6997 SN 1573-0646 JF Investigational New Drugs VO 36 IS 3 SP 416 OP 423 LK http://dx.doi.org/https://doi.org/10.1007/s10637-017-0513-5 DO https://doi.org/10.1007/s10637-017-0513-5 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)